\u201cOverall, we are extremely bullish on the future growth prospect of the combined Telix-ITM entity,\u201d William Blair analysts wrote in a Monday morning note, calling the deal \u201csupercritical\u201d as it deepens Telix\u2019s manufacturing capabilities and \u201cde-risks one of the most complex aspects of operating a radiopharmaceutical company.\u201d<\/p>\n
Telix and ITM expect to close the deal by the end of the year. The combined entity is projected to generate unaudited revenue and income topping $1.3 billion this year. Post-acquisition, Telix shareholders will own around 76.3% of the shares, while ITM backers will own around 23.7%.<\/p>\n
The transaction will further establish Telix as a \u201cvertically integrated radiopharmaceutical company,\u201d the release stated, strengthened by ITM\u2019s manufacturing infrastructure and distribution network covering more than 65 countries. Last year, ITM\u2019s revenue hit $273 million.<\/p>\n
ITM\u2019s production capabilities are key to the agreement, particularly given the difficulties of manufacturing radiopharmaceuticals, according to William Blair.<\/p>\n
\u201cBy building a vertically integrated company with even greater control over the entire radiopharmaceutical value chain, we believe the transaction will allow Telix to further corner the industry and advance a range of product candidates from development through commercialization,\u201d the analysts added.<\/p>\n
And then there\u2019s ITM\u2019s radiopharmaceutical asset ITM-11, which targets the somatostatin receptor for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NET). The candidate was rejected<\/a> by the FDA last month for issues with chemistry, manufacturing and controls at a third-party facility. No clinical safety or efficacy problems were identified, according to ITM.<\/p>\n <\/p>\n <\/a><\/p>\n \n ITM Isotope Technologies plans on resubmitting its advanced cancer radiopharma therapy to the FDA after addressing the agency\u2019s concerns.\n <\/p>\n August 11, 2026<\/p>\n \u00a0\u00b7\u00a0<\/p>\n 1 min read<\/p>\n \u00a0\u00b7\u00a0<\/p>\n ITM is currently reviewing the FDA\u2019s feedback and working with its external partners to address the agency\u2019s concerns. The private biotech plans to resubmit its application, though timing will depend on its remediation talks with the regulator, according to a Monday morning presentation from the company<\/a>. The buyout\u2019s contingent payments revolve around the initial and potential expansion approvals for ITM-11, as well as the asset\u2019s market performance.<\/p>\n Beyond GEP-NET, ITM\u2019s asset is also being developed for lung and thymic neuroendocrine tumors, for which the investigator-initiated Phase 3 LEVEL<\/a> trial is currently recruiting. Topline data for this study are expected in 2029.<\/p>\n If approved, ITM-11 could propel Telix into the radiopharma commercial ring, facing off against Novartis and its two lutetium-177-based products Lutathera<\/a> and Pluvicto<\/a>. The former is approved for GEP-NETs and made $816 million<\/a> last year, while the latter is indicated for metastatic castration-resistant prostate cancer with nearly $2 billion in 2025 revenues.<\/p>\n Other Big Pharmas are advancing<\/a> their own radiopharma assets, including AstraZeneca, Bristol Myers Squibb and Eli Lilly. Regeneron is also in the radiopharma ring, partnering with Telix in April<\/a> for up to $4.3 billion to use the biotech\u2019s platform for four programs initially, with the option to add four more later on.<\/p>\n![\"Cross](\"https:\/\/www.newsbeep.com\/nz\/wp-content\/uploads\/2026\/09\/1790406532_596_.jpeg\")
<\/p>\n
![](\"https:\/\/www.newsbeep.com\/nz\/wp-content\/uploads\/2026\/09\/1790406532_247_.png\")
<\/p>\n